News | August 01, 2025
Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
NewCo’s pipeline includes five investigational medicines
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
